Dmitry Balyasny’s CASI Pharmaceuticals CASI Stock Holding History

Dmitry Balyasny’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,317	Closed	-$32K	–	1988
2021 Q1	$32K	Buy	+1,317	New	+$37K	﹤0.01%	1695

Other funds holding CASI

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

IACGFIA

IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dmitry Balyasny's CASI Position: Q2 2021 in Review

Dmitry Balyasny sold out of CASI Pharmaceuticals (CASI) in Q2 2021, closing a stake of 1,317 shares — an estimated $32K sold.

Dmitry Balyasny first reported a position in CASI in Q1 2021 and held it in 1 quarter. The position peaked at $32K in Q1 2021. 68 funds tracked by Wall St. Rank hold CASI as of Q2 2021.

Dmitry Balyasny reported no remaining CASI Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Dmitry Balyasny sold 1,317 CASI Pharmaceuticals shares in Q2 2021, an estimated $32K.
Dmitry Balyasny first reported a position in CASI Pharmaceuticals in Q1 2021 and held it in 1 quarter.
Dmitry Balyasny's CASI Pharmaceuticals position peaked at $32K in Q1 2021.
68 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2021.

Based on Balyasny Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.